MA26644A1 - Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant - Google Patents

Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant

Info

Publication number
MA26644A1
MA26644A1 MA25616A MA25616A MA26644A1 MA 26644 A1 MA26644 A1 MA 26644A1 MA 25616 A MA25616 A MA 25616A MA 25616 A MA25616 A MA 25616A MA 26644 A1 MA26644 A1 MA 26644A1
Authority
MA
Morocco
Prior art keywords
diaza
nonane
spiro
derivatives
preparation
Prior art date
Application number
MA25616A
Other languages
English (en)
French (fr)
Inventor
Juergen Wichmann
Stephan Roever
Geo Adam
Andrea Cesura
Sabine Kolczewski
Francois Jenck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26644A1 publication Critical patent/MA26644A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
MA25616A 1998-06-12 1999-06-10 Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant MA26644A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110804 1998-06-12

Publications (1)

Publication Number Publication Date
MA26644A1 true MA26644A1 (fr) 2004-12-20

Family

ID=8232114

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25616A MA26644A1 (fr) 1998-06-12 1999-06-10 Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant

Country Status (28)

Country Link
US (1) US6113527A (Direct)
EP (1) EP0970957B1 (Direct)
JP (1) JP3286268B2 (Direct)
KR (1) KR100344732B1 (Direct)
CN (1) CN1107066C (Direct)
AR (1) AR019859A1 (Direct)
AT (1) ATE204279T1 (Direct)
AU (1) AU743983B2 (Direct)
BR (1) BR9902651A (Direct)
CA (1) CA2274202A1 (Direct)
DE (1) DE69900220T2 (Direct)
DK (1) DK0970957T3 (Direct)
ES (1) ES2162503T3 (Direct)
HR (1) HRP990188A2 (Direct)
HU (1) HU220894B1 (Direct)
ID (1) ID23304A (Direct)
IL (1) IL130377A0 (Direct)
MA (1) MA26644A1 (Direct)
NO (1) NO312590B1 (Direct)
NZ (1) NZ336189A (Direct)
PE (1) PE20000548A1 (Direct)
PL (1) PL333695A1 (Direct)
PT (1) PT970957E (Direct)
SG (1) SG79259A1 (Direct)
SI (1) SI0970957T1 (Direct)
TR (1) TR199901381A2 (Direct)
YU (1) YU26499A (Direct)
ZA (1) ZA993852B (Direct)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
JP4056977B2 (ja) * 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
BR0312414A (pt) 2002-07-05 2005-05-10 Targacept Inc Compostos de n-aril diazaespirociclico e métodos para a preparação e uso dos mesmos
EP1601674B1 (en) * 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
EP1784184A2 (en) * 2004-08-20 2007-05-16 Targacept, Inc. The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US8703948B2 (en) * 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
MX2009011006A (es) * 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
KR101704226B1 (ko) 2015-06-30 2017-02-07 현대자동차주식회사 자동차의 쿼터글라스 어셈블리
EP4452416A1 (en) * 2021-12-22 2024-10-30 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756743A (en) * 1996-04-10 1998-05-26 Hoechst Marion Roussel Inc. Spiro cyclopent b!indole-piperidines!

Also Published As

Publication number Publication date
HU220894B1 (en) 2002-06-29
IL130377A0 (en) 2000-06-01
YU26499A (sh) 2002-09-19
BR9902651A (pt) 2000-05-16
NO992873D0 (no) 1999-06-11
EP0970957B1 (en) 2001-08-16
AU743983B2 (en) 2002-02-14
NO992873L (no) 1999-12-13
HRP990188A2 (en) 2000-02-29
NO312590B1 (no) 2002-06-03
TR199901381A3 (tr) 2000-01-21
JP3286268B2 (ja) 2002-05-27
SI0970957T1 (Direct) 2001-12-31
ZA993852B (en) 1999-12-13
KR100344732B1 (ko) 2002-07-19
ES2162503T3 (es) 2001-12-16
PE20000548A1 (es) 2000-07-15
US6113527A (en) 2000-09-05
PL333695A1 (en) 1999-12-20
CA2274202A1 (en) 1999-12-12
HU9901911D0 (en) 1999-08-30
PT970957E (pt) 2002-02-28
DK0970957T3 (da) 2001-12-03
AR019859A1 (es) 2002-03-20
JP2000053679A (ja) 2000-02-22
DE69900220D1 (de) 2001-09-20
ID23304A (id) 2000-04-05
HUP9901911A1 (hu) 2000-05-28
DE69900220T2 (de) 2002-05-08
TR199901381A2 (xx) 2000-01-21
ATE204279T1 (de) 2001-09-15
KR20000006060A (ko) 2000-01-25
CN1242366A (zh) 2000-01-26
EP0970957A1 (en) 2000-01-12
AU3498799A (en) 1999-12-23
CN1107066C (zh) 2003-04-30
SG79259A1 (en) 2001-03-20
NZ336189A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
FR2786770B1 (fr) Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA23452A1 (fr) Procede de preparation d'agents antiparasitaires consistant en derives d'avermectines et de milbemycines.
FR2676230B1 (fr) Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
MA26644A1 (fr) Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant
FR2594438B1 (fr) Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
FR2735777B1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA23831A1 (fr) Derives de quinazoline, procede pour leur preparation et composition les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26537A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
MA26479A1 (fr) Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2722190B1 (fr) Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
MA26791A1 (fr) Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant.
FR2663326B2 (fr) Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2687401B1 (fr) Derives de la 1,4-dialkylpiperazine, procedes d'obtention et compositions pharmaceutiques les contenant.
FR2794646B1 (fr) Microgranules de sulfate de morphine, procede de preparation et composition les contenant
FR2597866B1 (fr) Derives du pyrazole, procede de preparation de ceux-ci et fongicide les contenant.
PL322802A1 (en) Derivatives of 10,13,15-trioxatricyclo[9.2.1.1]-pentadecanone, method of obtaining them and therapeutic agents containing such compounds
MA26413A1 (fr) DERIVES D'OCTAHYDRO-PYRROLO [1,2-a] PYRAZINE 2,7-SUBSTITUES, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA26441A1 (fr) Derives de pyrrolidinyl- et pyrrolinyl- ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26437A1 (fr) Derives de trans-piperazine-1-yl-spiro (cyclohexane-1,1'-isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2717811B1 (fr) Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
PT935598E (pt) Derivados de 3-oxo-pirido (1,2-a)benzimidazole-4-carboxamida alquilo substituidos contendo 5 heteroatomos uteis no tratamento de disturbios do sistema nervoso central
MA26606A1 (fr) Derives de 5-desoxycytidine, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation.